{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:52:24Z","timestamp":1791604344070,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cllc.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:41:29Z","timestamp":1787614889000},"page":"74-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and\/or Amplification: A Global Real-World Study"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-2960","authenticated-orcid":false,"given":"Julia","family":"Rotow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cuadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Roset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Pedros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacob","family":"Pinchevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongJin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cllc.2026.08.011_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.cllc.2026.08.011_bib0002","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.011_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.cllc.2026.08.011_bib0004","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2026.08.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.08.011_bib0006","unstructured":"ESMO. ESMO Living Guideline oncogene-addicted metastatic NSCLC: eGFR-activating mutation after systemic progression: if prior third-generation TKI. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-oncogene-addicted-metastatic-non-small-cell-lung-cancer\/management-of-advanced-and-metastatic-disease\/egfr-mutation\/stage-iv-mnsclc-with-egfr-activating-mutation-after-systemic-progression\/egfr-activating-mutation-after-systemic-progression-if-prior-third-generation-tki. Accessed: October 30, 2025."},{"key":"10.1016\/j.cllc.2026.08.011_bib0007","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.3.2026. \u00a9 National Comprehensive Cancer, Inc. 2026. All rights reserved. Accessed: November 10, 2025. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.cllc.2026.08.011_bib0008","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Central Nervous System Cancers V.3.2025. \u00a9 National Comprehensive Cancer, Inc. 2026. All rights reserved. Accessed: January 13, 2026. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"11","key":"10.1016\/j.cllc.2026.08.011_bib0009","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.011_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.011_bib0011","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: a multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung cancer treated with first-line osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.08.011_bib0012","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2340\/1651-226X.2025.44344","article-title":"Prevalence, molecular characterization, and prognosis of c-met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer","volume":"64","author":"Bar","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cllc.2026.08.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0604","article-title":"Evaluation of MET detection methods and cutoffs in EGFR-mutated non-small cell lung cancer following disease progression on osimertinib in the phase II SAVANNAH study","author":"Ahn","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2026.08.011_bib0014","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"16","key":"10.1016\/j.cllc.2026.08.011_bib0015","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0016","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12890-023-02482-9","article-title":"Clinicopathological characteristics of non-small cell lung cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification","volume":"23","author":"Ding","year":"2023","journal-title":"BMC Pulm Med"},{"issue":"5","key":"10.1016\/j.cllc.2026.08.011_bib0017","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.011_bib0018","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.011_bib0019","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2026.08.011_bib0020","first-page":"S468","article-title":"EP08.02-138 SAFFRON: ph3 savolitinib + osimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"10526","key":"10.1016\/j.cllc.2026.08.011_bib0021","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.011_bib0022","article-title":"LBA50 Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0023","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.cllc.2026.08.011_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112998","article-title":"The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications","volume":"15","author":"Feldt","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.cllc.2026.08.011_bib0025","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.08.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103894","article-title":"Long-term impact of first-line amivantamab plus lazertinib versus osimertinib on mechanisms of acquired resistance in MARIPOSA: a brief report","author":"Hayashi","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.08.011_bib0027","unstructured":"US Food & Drug Administration (FDA). RYBREVANT (amivantamab). Highlights of Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761210s003lbl.pdf. Accessed: June 2026."},{"issue":"18","key":"10.1016\/j.cllc.2026.08.011_bib0028","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","article-title":"Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models","volume":"9","author":"Gavine","year":"2015","journal-title":"Mol Oncol"},{"issue":"16","key":"10.1016\/j.cllc.2026.08.011_bib0030","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/1078-0432.CCR-18-1189","article-title":"First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity","volume":"25","author":"Gan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.cllc.2026.08.011_bib0031","article-title":"Abstract CT305: phase I studies of a selective cMet inhibitor AZD6094 (HMPL504\/volitinib) in patients with advanced solid tumors","volume":"75","author":"Hua","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.cllc.2026.08.011_bib0032","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1158\/1538-7445.AM2025-4353","article-title":"Abstract 4353: a phase I open-label positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers","volume":"85","author":"Miah","year":"2025","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.011_bib0033","article-title":"Long-term efficacy, safety, and subgroup analysis of savolitinib in Chinese patients with NSCLCs harboring MET exon 14 skipping alterations","volume":"3","author":"Lu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2026.08.011_bib0034","unstructured":"ClinicalTrials.gov. NCT05261399: savolitinib plus osimertinib versus platinum-based doublet chemotherapy in participants with non-small cell lung cancer who have progressed on osimertinib treatment (SAFFRON). https:\/\/clinicaltrials.gov\/study\/NCT05261399. Accessed: October 30, 2025."},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40801-021-00272-5","article-title":"Treatment patterns in patients with locally advanced or metastatic non-small-cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: analysis of US insurance claims databases","volume":"9","author":"Soo","year":"2022","journal-title":"Drugs Real World Outcomes"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13889","article-title":"Plasma cell-free DNA genotyping: from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer","volume":"26","author":"Gray","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2026.08.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221116834","article-title":"Concordance of genomic profiles in matched tissue and plasma samples from Chinese patients with lung cancer","volume":"16","author":"He","year":"2022","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0038","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.08.011_bib0039","unstructured":"International Association for the Study of Lung Cancer (IASLC). IASLC Atlas of molecular testing for targeted therapy in lung cancer | IASLC. 2023. https:\/\/www.iaslc.org\/iaslc-atlas-molecular-testing-targeted-therapy-lung-cancer. Accessed: December 02, 2025."},{"issue":"12","key":"10.1016\/j.cllc.2026.08.011_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103996","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.011_bib0041","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/tlcr.2020.04.07","article-title":"Lung cancer biomarker testing: perspective from Europe","volume":"9","author":"Thunnissen","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2026.08.011_bib0042","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241290733","article-title":"Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer","volume":"16","author":"Ye","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2026.08.011_bib0043","first-page":"83","article-title":"Prognostic and predictive value of MET deregulation in non-small cell lung cancer","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.011_bib0044","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.jtho.2025.09.114","article-title":"MA03.03 SAVANNAH: biomarker concordance and acquired resistance in patients with EGFRm MET-OverExp and \/or Amp NSCLC","volume":"20","author":"Baik","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.08.011_bib0045","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression. Accessed: November 10, 2025."},{"issue":"25","key":"10.1016\/j.cllc.2026.08.011_bib0046","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.cllc.2026.08.011_bib0047","article-title":"Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: analysis of tissue IHC and ctDNA NGS","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.09.154","article-title":"MA07.07 Validation analysis of MET IHC as a biomarker for amivantamab-lazertinib response in post-osimertinib EGFR-mutated NSCLC","volume":"20","author":"Besse","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.08.011_bib0049","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.cllc.2026.08.011_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.cllc.2026.08.011_bib0051","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:25:27Z","timestamp":1791602727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1525730426001154"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and\/or Amplification: A Global Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}